New technologies for influenza vaccines

49Citations
Citations of this article
40Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Influenza vaccine preparations have been administered to humans since the late 1930s,1 and the diversity of approaches in licensed trivalent seasonal or monovalent pandemic products is unparalleled by vaccines against any other target. These approaches include inactivated whole virus vaccines, detergent or solvent "split" vaccines, subunit vaccines, live attenuated vaccines, adjuvanted vaccines, intramuscular vaccines, intradermal vaccines, intranasal vaccines, egg-produced vaccines and mammalian cell culture-produced vaccines. The challenges of influenza immunization, including multiple cocirculating strains, antigenic change over time, a road age spectrum of disease, and the threat of pandemics, continue to drive the development of new approaches. This review describes some of the new approaches to influenza immunization that are the subjects of active research and development. © 2012 Landes Bioscience.

Cite

CITATION STYLE

APA

Dormitzer, P. R., Tsai, T. F., & Del Giudice, G. (2012). New technologies for influenza vaccines. Human Vaccines and Immunotherapeutics. https://doi.org/10.4161/hv.8.1.18859

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free